Dasatinib and Dexamethasone Combination Therapy Targets Myeloma and the Tumor Microenvironment

被引：0
|
作者：
Ramasamy, K. A. [1 ]
Macpherson, L. [1 ]
Mufti, G. [1 ]
Schey, S. [1 ]
Calle, Y. [1 ]
机构：
[1] Kings Coll London, London, England
来源：
CLINICAL LYMPHOMA & MYELOMA | 2009年 / 9卷
关键词：
D O I：
10.1016/S1557-9190(11)70692-8
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S116 / S117
页数：2
相关论文
共 50 条
  • [1] Targeting tumor microenvironment for multiple myeloma therapy
    Pandey, M.
    CANCER MEDICINE, 2018, 7 : 8 - 8
  • [2] Bone marrow microenvironment and the identification of new targets for myeloma therapy
    Podar, K.
    Chauhan, D.
    Anderson, K. C.
    LEUKEMIA, 2009, 23 (01) : 10 - 24
  • [3] Bone marrow microenvironment and the identification of new targets for myeloma therapy
    K Podar
    D Chauhan
    K C Anderson
    Leukemia, 2009, 23 : 10 - 24
  • [4] Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma
    Rajkumar, SV
    Hayman, S
    Gertz, MA
    Dispenzieri, A
    Lacy, MQ
    Greipp, PR
    Geyer, S
    Iturria, N
    Fonseca, R
    Lust, JA
    Kyle, RA
    Witzig, TE
    JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (21) : 4319 - 4323
  • [5] Quisinostat, bortezomib, and dexamethasone combination therapy for relapsed multiple myeloma
    Moreau, Philippe
    Facon, Thierry
    Touzeau, Cyrille
    Benboubker, Lotfi
    Delain, Martine
    Badamo-Dotzis, Julie
    Phelps, Charles
    Doty, Christopher
    Smit, Hans
    Fourneau, Nele
    Forslund, Ann
    Hellemans, Peter
    Leleu, Xavier
    LEUKEMIA & LYMPHOMA, 2016, 57 (07) : 1546 - 1559
  • [6] Elotuzumab-Iberdomide-Dexamethasone Combination Therapy Activates T and NK Cells within the Immune Microenvironment of Multiple Myeloma Patients
    Chen, Lucia Y.
    Amatangelo, Michael
    Aleman, Adolfo
    Van Oekelen, Oliver
    Nevers, Tania
    Sun, Yongliang
    Pierceall, William E.
    Kappes, Katerina
    Blangiardo, Anna
    Jagannath, Sundar
    Rodriguez, Cesar
    Parekh, Samir
    BLOOD, 2024, 144 : 6860 - 6861
  • [7] Combination Therapy with Thalidomide, Incadronate, and Dexamethasone for Relapsed or Refractory Multiple Myeloma
    Naoya Ochiai
    Noriko Yamada
    Ryo Uchida
    Shin-ichi Fuchida
    Akira Okano
    Mayumi Hatsuse
    Masashi Okamoto
    Eishi Ashihara
    Chihiro Shimazaki
    International Journal of Hematology, 2005, 82 : 243 - 247
  • [8] Combination therapy with thalidomide, incadronate, and dexamethasone for relapsed or refractory multiple myeloma
    Ochiai, N
    Yamada, N
    Uchida, R
    Fuchida, S
    Okano, A
    Hatsuse, M
    Okamoto, M
    Ashihara, E
    Shimazaki, C
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2005, 82 (03) : 243 - 247
  • [9] THE EFFICACY OF COMBINATION THERAPY WITH LENALIDOMIDE AND DEXAMETHASONE IN THE TREATMENT OF RELAPSED MULTIPLE MYELOMA
    Szudy-Szczyrek, Aneta
    Legiec, Wojciech
    Manko, Joanna
    Gmyz, Katarzyna
    Szczyrek, Michal
    Hus, Marek
    HEALTH PROBLEMS OF CIVILIZATION, 2015, 9 (02) : 50 - 54
  • [10] Dasatinib in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma: Preliminary Results of a Phase I Study
    Facon, Thierry
    Leleu, Xavier
    Stewart, A. Keith
    Spencer, Andrew
    Rowlings, Philip
    Hulin, Cyrille
    Attal, Michel
    Garzon, Felix
    Bleickardt, Eric
    Gialelis, Konstantina
    Tuozzoli, Doreen
    Derreumaux, Dorninique
    Sonneveld, Pieter
    BLOOD, 2009, 114 (22) : 744 - 745
12345